Table 1.
Characteristics of patients aged 18–65 years who received a first HLA-identical sibling PBSC or BM transplants for hematologic malignancies from 1999–2003. Patients received Fludarabine + Busulfan + Thymoglobulin (cases) or Busulfan + Cyclophosphamide (controls).
|
CASES FluBuTG |
CONTROLS BuCy |
||||
|---|---|---|---|---|---|
| Characteristics of patients | N eval | N (%) | N eval | N (%) | P-valuea |
| Number of patients | 120 | 215 | |||
| Number of centers | 1 | 62 | |||
| Age at transplant, median (range), years | 120 | 46 (18–65) | 215 | 44 (18–63) | |
| 18–45 | 57 (48) | 120 (56) | 0.01 | ||
| 46–65 | 63 (52) | 95 (44) | |||
| Male sex | 120 | 72 (60) | 215 | 127 (59) | 0.87 |
| Matching Groups | 120 | 215 | --** | ||
| AML, ALL, CML early(CR1, CP1)b | 52 (44) | 104 (48) | |||
| AML, ALL, CML intermediate (CR2+, CP2+, AP)b | 4 (3) | 8 (4) | |||
| AML, ALL, CML advanced (PIF, REL, BP)b | 13 (11) | 26 (12) | |||
| MDS Treated | 4 (3) | 8 (4) | |||
| MDS Untreated | 18 (15) | 36 (17) | |||
| Multiple Myeloma | 8 (8) | 8 (4) | |||
| NHL/HL PIF or REL | 14 (12) | 14 (6) | |||
| NHL/HL CR | 4 (3) | 8 (4) | |||
| CLLc | 3 (2) | 3 (1) | |||
| Karnofsky score prior to transplant | 120 | 208 | <0.001 | ||
| < 90 | 84 (70) | 36 (17) | |||
| ≥ 90 | 36 (30) | 172 (83) | |||
| Graft type | 120 | 215 | |||
| BM | 21 (17) | 87 (40) | <0.001 | ||
| PBSC | 99 (83) | 128 (60) | |||
| Time from diagnosis to transplant, median (range), months | 118 | 5 (<1–154) | 215 | 6 (<1–209) | |
| ≤ 6 months | 66 (56) | 103 (48) | 0.03 | ||
| > 6 months | 52 (44) | 112 (52) | |||
| Donor-recipient CMV status | 114 | 204 | 0.25 | ||
| Negative/Negative | 22 (19) | 51 (25) | |||
| At least one positive | 92 (81) | 153 (75) | |||
| Donor-recipient sex match | 120 | 214 | 0.89 | ||
| F-M | 34 (28) | 63 (29) | |||
| Otherd | 86 (72) | 151 (71) | |||
| GVHD prophylaxis | 120 | 215 | |||
| MTX + CSA only | 120 (100) | 215 (100) | |||
| Year of transplant | 120 | 215 | <0.001 | ||
| 1999–2000 | 44 (37) | 146 (68) | |||
| 2001–2003 | 76 (63) | 69 (32) | |||
| Year of diagnosis | 118 | 215 | 0.07 | ||
| 1982–1996 | 4 (3) | 14 (7) | |||
| 1997–2003 | 114 (97) | 201 (93) | |||
| Median follow-up of survivors, months | 69 | 60 (16–95) | 115 | 54 (3–93) | |
Abbreviations: AML=acute myelogenous leukemia; ALL=acute lymphoblastic leukemia; CLL=chronic lymphocytic leukemia; CML=chronic myelogenous leukemia; NHL=non-Hodgkin lymphoma; HL= Hodgkin lymphoma; MDS/MPS=myelodysplastic/myeloproliferative disorders; CR= complete remission; REL= relapse; PIF= primary induction failure; CP= chronic phase; AP= accelerated phase; BP=blast phase; CSA= cyclosporine; MTX= methotrexate; BuCy= oral busulfan + cyclophosphamide; FluBuTG= fludarabine + IV busulfan + thymoglobulin; BM= bone marrow; PBSC= peripheral blood stem cells; RIC= reduced intensity conditioning; EVAL=evaluable; CMV= cytomegalovirus virus; F=female; M=male; HLA=human leukocyte antigen.
The conditional logistic regression test was used for discrete covariates to detect the significant difference to for matched pair.
| Disease | Cases | Controls | ||
|---|---|---|---|---|
| CML | 21 | 76 | ||
| 1st Chronic phase | 19 | 69 | ||
| 2nd Chronic phase | - | 2 | ||
| ≥ 2nd Chronic phase | 2 | 2 | ||
| Blast phase | - | 3 | ||
| AML | 46 | 55 | ||
| Primary induction failure | 6 | 10 | ||
| CR1 | 30 | 31 | ||
| CR2 | 2 | 2 | ||
| REL1 | 7 | 9 | ||
| ≥ REL2 | 1 | 3 | ||
| ALL | 2 | 6 | ||
| CR1 | 2 | 3 | ||
| CR2 | - | 1 | ||
| CR3 | - | 1 | ||
| REL1 | - | 1 |
The two other CLL disease statuses are RAI stage 0 and RAI stage III.
Other Donor-recipient sex match included: Male-Male (n=101); Male-Female (n=53); Female-Female (n=83).
Matched variables.